MARI — Marinomed Biotech AG Balance Sheet
0.000.00%
Last trade - 00:00- €36.98m
- €46.21m
- €4.75m
- 39
- 90
- 95
- 92
Annual balance sheet for Marinomed Biotech AG, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 9.21 | 5.8 | 8.18 | 2.59 | 1.71 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 5.18 | 4.81 | 3.12 | 2.39 | 0.907 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 15.4 | 12.9 | 14.3 | 7.14 | 3.29 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 6.04 | 6.43 | 6.2 | 5.94 | 4.79 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 23.5 | 21.3 | 22.3 | 14.6 | 8.18 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 5.61 | 6.01 | 5.96 | 9.65 | 5 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 18.1 | 21.1 | 26.4 | 24.7 | 34.3 |
| Common Stock | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 5.36 | 0.191 | -4.16 | -10.1 | -26.2 |
| Total Liabilities & Shareholders' Equity | 23.5 | 21.3 | 22.3 | 14.6 | 8.18 |
| Total Common Shares Outstanding |